

CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING

Athens, Greece

Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia; Ivanov, Nikolai; Luedicke, Frank; Maeder, Serge; Peitsch, Manuel; Phillips, Blaine; Poussin, Carine; Vanscheeuwijck, Patrick

Philip Morris International 9 June 2018

The Scientists



Gizelle Baker



Christelle Haziza



Frank Luedicke



Serge Maeder



Patrick Picavet



Carine Poussin



PMI SCIENCE PHILIP MORRIS INTERNATIONAL



Nikolai Ivanov



Manuel Peitsch

Julia Hoeng



Blaine Phillips



Patrick Vanscheeuwijck

Creating a New Category: Reduced-Risk Products



Reduced-Risk Products ("RRPs") is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking.

We have a range of RRPs in various stages of development, scientific assessment, and commercialization.

Because our RRPs do not burn tobacco, they produce far lower quantities of harmful and potentially harmful compounds than found in cigarette smoke.




Tobacco Harm Reduction

What Is the Objective of Harm Reduction?

- Smoking is addictive and causes a number of serious diseases
- Worldwide, it is estimated that more than 1 billion people will continue to smoke in the foreseeable future^{*}
- Offering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies

1,000,000,000



Successful harm reduction requires that current adult smokers be offered a range of Reduced-Risk Products they can fully switched to, should they decide not to quit.

* http://www.who.int/tobacco/publications/surveillance/reportontrendstobaccosmoking/en/index4.html


Figure adapted from Clive Bates presentation to E-Cigarette Summit (19 Nov 2013)

Note: Reduced Risk Products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switched to these products versus continued smoking.



Excess Risk of Smoking-Related Disease


Disease-Specific Relative Risk ^[1] (by age) *Relative risk of IHD, Stroke, COPD, and LC for an adult cigarette smoker*



PHILIP MORRIS INTERNATIONAL

Excess Risk of Smoking-Related Disease

Reduction in Excess Risk Over Time



Disease Risk Half-Life ^[2] (The time at which half of the Excess risk associated with cigarette smoking has disappeared)

Age (a)	Lung Cancer	IHD	Stroke	COPD
Any age	-	-	4.78	13.32
to 49	6.98	1.47	-	-
50 to 59	10.39	5.22	-	-
60 to 69	10.60	7.48	-	-
70 to 79	12.99	13.77	-	-

[1] Sources for relative risk: Lung Cancer (Lee 2012), COPD (Forey 2011), IHD and Stroke (Lee 2016)

[2] Sources for half-life of risk: Lung Cancer (Fry 2013), COPD (Lee 2014), IHD (Lee 2012), Stroke (Lee 2014)






Combustion

Elimination of Combustion Is Key

Scientific studies have shown that as the temperature of tobacco increases, the levels of harmful chemicals formed increases



PMI SCIENCE PHILIP MORRIS INTERNATIONAL



The Tobacco Heating System 2.2

PMI's Reduced-Risk Product Portfolio




Note: The RRPs depicted are subject to ongoing development; therefore, the descriptions are illustrative and do not necessarily represent the latest stages of product development.




Why Heat Tobacco Rather than Burn It?

The Tobacco Heating System (THS) (currently commercialized as *IQOS* in > 38 countries) is designed and has been demonstrated to:

- Heat tobacco <u>without</u> combustion
- Preserve elements of the taste, sensory experience, nicotine delivery profile, and ritual characteristics of cigarettes






PHILIP MORRIS INTERNATIONAL



Scientific Assessment Approach

PMI's Scientific Assessment Approach



Post-Market Studies and Surveillance **Consumer Perception and Behavior** Assessment **Clinical Trials** Systems Toxicology Assessment **Standard Toxicology Assessment**


Aerosol Chemistry and Physics

Product Design and Control Principles



Source: Smith, M.R., et al., Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regulatory Toxicology and Pharmacology (2016). http://dx.doi.org/10.1016/j.yrtph.2016.07.006


Assessment Framework: Informed by Epidemiology





Exposure Reduction and Carbon-Based Nanoparticles

Reduced Formation of HPHCs by Disease Categories



Note: Intense Health Canada's Smoking Regime; Comparison on a per-stick basis; Excludes Nicotine

PHILIP MORRIS INTERNATIONAL

Changes in Exposure to HPHCs

Leads to

Smoking Abstinence

Leads to

Cigarette

THS

Reduced Exposure in Healthy Human Subjects

Levels of HPHCs are Drastically Reduced in THS Aerosol

- 98.6%*

0.48

- 98.0%*

5.52

33.3

282

35

30

5

0

300


250

NNK (ng/stick) 120 100

50

Ο


Exposure is Significantly Reduced After Switching to THS




* On equivalent nicotine basis

Reduced Exposure Similar to Smoking Abstinence


Reduced Exposure in Healthy Human Subjects




Reduced Formation of HPHCs by Disease Categories



Scanning Electron Microscopy images of the collected smoke/aerosol after passing through a thermodenuder set at 300° C to remove the volatile portion / collected material characterized by Electron Diffusive X-ray.



Global Disease Risk Associated with PM 2.5



SD-654

Global Burden of Diseases Study 2015. Lancet 2017; 1907-1918.



In Vitro Models of Disease


From Risk Assessment Framework to In Vitro Study Design

In vitro model: Adhesion of monocytic cells to human coronary arterial endothelial cells

- 1. Cell exposure to 3R4F or THS 2.2 (aqueous smoke / aerosol extract)
- 2. Treatment of human coronary arterial endothelial cells (HCAEC)


3. Adhesion Assay

- Untreated MM6 cells and 4h-treated HCAECs were nuclearstained for 15 min. and then incubated together for 45 min
- After cell fixing and washing, remaining adherent MM6 cells and HCAECs were counted
- The adhesion rate was calculated



The number of adherent MM6 cells and the number of HCAECs

Poussin et al. Systems toxicology-based assessment of the candidate modified risk tobacco product THS2.2 for the adhesion of monocytic cells to human coronary arterial endothelial cells. *Toxicology 2016*; 73–86.





From Risk Assessment Framework to In Vitro Study Design

In vitro model: Adhesion of monocytic cells to human coronary arterial endothelial cells





Figure 1: Effects of THS2.2 abPBS and 3R4F sbPBS on the adhesion of MM6 cells to HCAECs following indirect, direct, and fresh direct treatments of HCAECs. Bar charts represent fold changes of the adhesion rate relative to respective vehicle controls. The adhesion rate reflects the number of adherent MM6 cells relative to the total number of HCAECs counted in the same well multiplied by 100. Data are presented as the mean \pm SEM; N=2–3 independent experiments (n=3–6 replicates). *p≤0.05, ***p≤0.001 vs. 0 puffs/ml (PBS 15% or 75%).



Poussin et al. Systems toxicology-based assessment of the candidate modified risk tobacco product THS2.2 for the adhesion of monocytic cells to human coronary arterial endothelial cells. *Toxicology 2016*; 73–86.

From Risk Assessment Framework to In Vitro Study Design

In vitro model: Adhesion of monocytic cells to human coronary arterial endothelial cells



Conclusions:

- 3R4F aqueous cigarette smoke extract promoted adhesion of MM6 cells to HCAEC in indirect and fresh direct exposure conditions
- At the same concentrations, no significant adhesion of MM6 cells to HCAECs
- The concentrations of THS 2.2 required to be increased by ~10 and 20 times to observe similar effects at functional and molecular levels to the ones observed with 3R4F



Poussin et al. Systems toxicology-based assessment of the candidate modified risk tobacco product THS2.2 for the adhesion of monocytic cells to human coronary arterial endothelial cells. *Toxicology 2016*; 73–86.




Animal Models of Disease

From Risk Assessment Framework to in vivo Study Design

Animal Model: ApoE -/- mouse – Concomitant analysis of CVD and COPD endpoints


- 8 months duration (approximately 40% of lifetime)
- Concomitant analysis of CVD and COPD endpoints
- Comprehensive analysis of molecular changes and mechanistic impact
- Exposure dose corresponds to ~30 cigarettes per day in human comparison



MORRIS INTERNATIONAL

Phillips *et al.* (2015) An 8-Month Systems Toxicology Inhalation/Cessation Study in Apo e-/- Mice to Investigate Cardiovascular and Respiratory Exposure Effects of a Candidate Modified Risk Tobacco Product, THS 2.2, Compared with Conventional Cigarettes. Toxicological Sciences, in press

Reduced Effects on Disease Mechanisms




8-month Apoe-/- mouse switching study Interaction between monocytes and endothelial cells

Network Perturbation Amplitude of:

NPA

- Inflammation/Endothelial cell activation igslash
- Inflammation/Neutrophil Signaling ψ







Monocyte Adhesion to ECs

Step

Heart (left ventricle) Transcriptomics






- Muscle structure and function
- Inflammatory response
- > Cardiovascular disease



Szostak, J., et al. (2017). "Aerosol from Tobacco Heating System 2.2 has reduced impact on mouse heart gene expression compared with cigarette smoke." Food and Chemical Toxicology 101: 157-167.


From Risk Assessment Framework to in vivo Study Design



Phillips, B., et al. (2015). "An 8-month systems toxicology inhalation/cessation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of a candidate modified risk tobacco product, THS 2.2, compared with conventional cigarettes." <u>Toxicological Sciences 149(2): 411-432.</u>



Atherosclerotic Plaque in the Aortic Arch Data from μ CT at month 7



MORRIS INTERNATIONAL


Phillips, B., et al. (2015). "An 8-month systems toxicology inhalation/cessation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of a candidate modified risk tobacco product, THS 2.2, compared with conventional cigarettes." Toxicological Sciences 149(2): 411-432.

Atherosclerotic Plaque in the Aortic Arch Data from µCT at month 7

Disease Endpoint for CVD

Atherosclerotic Plaque in the Aortic Arch

Data from μ CT at month 7




Phillips, B., et al. (2015). "An 8-month systems toxicology inhalation/cessation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of a candidate modified risk tobacco product, THS 2.2, compared with conventional cigarettes." Toxicological Sciences 149(2): 411-432.




Exposure Response Study

Clinical Assessment - Results to Date



*Harmful and potentially harmful constituents

Primary Objective and Co-Primary Endpoints



Study Population - Main Eligibility Criteria

Healthy subjects. Minimum 30 year of age.

10 years of smoking history with at least 10 CC/day for the last year

Subjects did not intent to quit smoking

Clinically relevant disorders that would jeopardize the participants safety

Female, not pregnant or breast feeding


Subjects did use medication with an impact on co-primary endpoints

Green Frame: Inclusion Criteria

Red Frame: Exclusion Criteria



Study Design and Disposition - Exposure Response Study





Statistical Analysis

Success Criteria:

To establish that the risk profile of THS is modified compared to cigarettes




<u>All</u> co-primary endpoints shift in the direction of cessation



≥ 5 out of 8 clinical risk endpoints are statistically significant (Hailperin-Rüger Approach)





PMI SCIENCE PHILIP MORRIS INTERNATIONAL

*By using a 1-sided test with the Hailperin-Rüger adjusted α level for multiple testing (1.5625%).

Analysis Populations Reduced Exposure Studies vs Exposure Response Study

Primary Analysis PopulationPrimary Assessment Objective3 months Reduced Exposure StudyUse of no more than 2 CC in a single day
during the 30 days preceding the visitAnalysis of the effect of THS after full
switchingAverage product use within a 3-month
period of not more than 0.5 CC/daySecond Comparison

6 months Exposure Response Study


- Analysis population: THS 2.2 as it is actually used
- ≥70% THS use over the 6-month analysis period
- ≥70% THS use on >50% of days in the 6month analysis period

Analysis of the effect of THS as actually used (up to 30% use of cigarettes)



PMI SCIENCE HILIP MORRIS INTERNATIONAL

Main Analysis Population



* Calculated over the study and on at least 50% of the Study Days




Product Use

Time Period	Product	THS Use Mean / Day (Min, Max)	CC Use Mean / Day (Min, Max)
Baseline	Cigarettes	18.5 (10.0, 65.0)	19.5 (10.0, 90.0)
Post- randomization	THS	16.5 (3.2, 63.0)	< 0.01 (0.0, 0.44)
	Cigarettes	1.95 (0.0, 14.0)	16.8 (3.0, 43.7)
	Overall tobacco	18.5 (3.2, 63.5)	16.9 (3.1, 43.7)



Reduction in Exposure and Exposure to Nicotine





Clinical Changes After 90 Days Reduced Exposure in Healthy Human Subjects

Disease Pathway	Endpoint	Abstinence Effect at 3m [95% CI]		Switching to THS Effect at 3m [95%CI]	
Lipid Metabolism	HDL-C	0.0 mg/dL [-5.77; 5.84]		1.4 mg/dL [-2.3;5.0]	
Inflammation	WBC	-0.94 10 ⁹ /L [-2.00; 0.13]	-	0.17 10 ⁹ /L [-0.47; 0.81]	
Airway Impairment	FEV1	2.0 % pred [-3.37; 7.36]		0.53 % pred [-2.79; 3.85]	
Endothelial Dysfunction	sICAM-1	-9.9 % [-19.7;1.1]	₽	-10.6 % [-16.7; -4.0]	
Oxidative Stress	8-epi-PGF2α	-8.5 % [-25.13; 11.8]	➡	-13.5 % [-23.6;-1.95]	
Clotting	11-DTX-B2	-7.2 % [-37.7; 38.3]	•	-3.6 % [-24.6; 23.3]	
Diacasa Dathway		Abstinence Effect		Switching to THS Effect	
Disease Pathway	Endpoint	at 3m [95% CI]		at 3m [95% CI]	
Lipid Metabolism	Endpoint HDL-C	at 3m [95% CI] 6.4 mg/dL [2.5; 10.3]	1	at 3m [95% CI] 4.5 mg/dL [1.17, 7.88]	
•	-		1		
Lipid Metabolism	HDL-C	6.4 mg/dL [2.5; 10.3]	↑ ↓ ↑	4.5 mg/dL [1.17, 7.88]	
Lipid Metabolism Inflammation	HDL-C WBC	6.4 mg/dL [2.5; 10.3] -0.41 10 ⁹ /L [-0.95; 0.14]	1 + 1 +	4.5 mg/dL [1.17, 7.88] -0.57 10 ⁹ /L [-1.04, -0.10]	
Lipid Metabolism Inflammation Airway Impairment	HDL-C WBC FEV ₁	6.4 mg/dL [2.5; 10.3] -0.41 10 ⁹ /L [-0.95; 0.14] 1.94 % pred [-0.44; 4.31]	↑ ↓ ↑ ↓	4.5 mg/dL [1.17, 7.88] -0.57 10 ⁹ /L [-1.04, -0.10] 1.91 % pred [-0.14, 3.97]	

0

Changes in Clinical Risk Endpoints


Endpoint	Change From CC-use	Observed Change LS Mean Difference / Relative Reduction	Halparin Ruger Adjusted Cl	1-sided p-value (0.0156)	THS directional change vs SA (literature)
HDL-C	Difference	3.09 mg/dL	1.10, 5.09	<0.001*	✓ significant
WBC Count	Difference	-0.420 GI/L	-0.717, -0.123	0.001*	✓ significant
sICAM-1	% Reduction	2.86 %	-0.426, 6.04	0.030	\checkmark
11-DTX-B2	% Reduction	4.74 %	-7.50, 15.6	0.193	\checkmark
8-epi-PGF2α	% Reduction	6.80 %	-0.216, 13.3	0.018	\checkmark
COHb	% Reduction	32.2 %	24.5, 39.0	<0.001*	✓ significant
FEV1 %pred	Difference	1.28 %pred	0.145, 2.42	0.008*	✓significant
Total NNAL	% Reduction	43.5 %	33.7, 51.9	<0.001*	✓significant

* denotes significant p value at the 1.5625% level, following test multiplicity adjustment using the Hailperin-Rüger approach

- All CRE shifted in the same direction as smoking cessation effect observed in the literature
- 5 out of 8 clinical risk endpoints were statistically significant compared to continued smoking



Changes in Clinical Risk Endpoints When Adjusted for CEMA Exposure Levels



Note: The predominant THS Use category group was stratified by CEMA quartiles 1 (bottom) to 4 (top). Note: Higher CEMA levels are indicative of higher levels of cigarette smoking. The panel for sICAM-1 shows the THS vs. continued smoking LS means ratios. The panel for leukocytes (WBC) shows the THS minus cigarette smoking LS means differences.




Conclusion of the Exposure Response Study

- All clinical risk endpoints shifted in the same direction as the smoking cessation effect described in the literature
- 5 out of 8 endpoints showed statistically significant and favorable changes after switching to THS....
-despite the fact that up to 30% CC use was allowed in the primary analysis population
- Full switching is the best option for current adult smokers continuing to use tobacco products



Summary



Phillips B, Veljkovic E, Boue S, Schlage WK, Vuillaume G, Martin F, et al. An 8-Month Systems Toxicology Inhalation/Cessation Study in Apoe-/- Mice to Investigate

Cardiovascular and Respiratory Exposure Effects of a Candidate Modified Risk Tobacco Product, THS 2.2, Compared With Conventional Cigarettes. Toxicological sciences : an official journal of the Society of Toxicology. 2016 Feb;149(2):411-32.

PMI SCIENO

PHILIP MORRIS INTERNATIONAL



Thank you for your attention